New Drug Approvals

Home » 2013 (Page 85)

Yearly Archives: 2013

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,886,988 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.8K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.8K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Catenane synthesis is studied with the aim of producing molecular switches for use in molecular memory devices


Making Molecular Switches

Catenane synthesis is studied with the aim of producing molecular switches for use in molecular memory devices

Read more

Magnetic Nanoparticles Detect Pathogens


thumbnail image: Magnetic Nanoparticles Detect Pathogens

Magnetic Nanoparticles Detect Pathogens

A novel iron oxide nanoparticle-based system detects pathogens with high sensitivity, specificity, and rapidity

Read more at wiley

Nanomachine Drug Delivery


Nanomachine Drug Delivery

A sensing–actuating nanomachine based on Janus Au–mesoporous silica nanoparticles for enzyme-controlled cargo release

Read more at wiley

Congress, FDA Should Look to Existing Technology to Make Pharmacy Compounding Safer


Last fall’s deadly meningitis outbreak linked to contaminated steroid injections is a tragic reminder of the risk of errors inherent in manual pharmacy medication compounding. Unsanitary conditions at the Massachusetts compounding pharmacy that made the injections resulted in fungal contamination of the drugs. The resulting outbreak sickened nearly 700 people in 19 states, and killed more than 40.

read all at

http://www.pharmpro.com/blogs/2013/03/congress-fda-should-look-existing-technology-make-pharmacy-compounding-safer

 

 

New Drug May Help Immune System Fight Cancer


May 16, 2013 — An experimental drug that taps the power of the body’s immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows.

read all at

http://www.drugs.com/news/new-may-help-immune-fight-cancer-44582.html

Roche files next-generation Rituxan in USA, EU


 

 

Roche files next-generation Rituxan in USA, EU

Roche has filed obinutuzumab on both sides of the Atlantic to treat chronic lymphocytic leukaemia.May 16, 2013

read all at

http://www.pharmatimes.com/Article/13-05-16/Roche_files_next-generation_Rituxan_in_USA_EU.aspx

 

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human CD20 (
antigen)) (human-mouse monoclonal GA101
heavy chain), disulfide with human-mouse monoclonal GA101k chain, dimer

Bayer initiates phase 3 trials of stivarga, regorafenib, in patients with advanced liver cancer


 

 

read all at

http://www.sacbee.com/2013/05/14/5421364/bayer-initiates-phase-iii-trial.html

TaiGen Biotechnology Announces Submission of New Drug Application for Nemonoxacin in Taiwan and Mainland china


FIG. 1.

nemonoxacin malate

TAIPEI, Taiwan, May 16, 2013

TaiGen Biotechnology Company, Limited (“TaiGen”) today announced that they have submitted New Drug Application (NDA) for the oral formulation of nemonoxacin with the Taiwan Food and Drug Administration (TFDA) and China Food and Drug Administration (CFDA). Approval is expected in the first half of 2014.

Read more here: http://www.heraldonline.com/2013/05/16/4866550/taigen-biotechnology-announces.html

First patient enrolled into Phase III moxetumomab study, AstraZeneca accelerates cancer drug testing


LONDON, May 16 2013

 AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukaemia as the group’s new CEO delivers on a promise to accelerate its oncology programmes.

Britain’s second-biggest drugmaker said on Thursday the Phase III clinical trial would test moxetumomab pasudotox in patients with hairy cell leukaemia who have not responded to or have relapsed after standard therapy.

FDA to review extended use of Seattle Genetics’ Adcetris (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).


 

FDA approves Seattle Genetics Adcetris cancer treatment

READ ALL AT

http://www.pharmatimes.com/Article/13-05-15/FDA_to_review_extended_use_of_Seattle_Genetics_Adcetris.aspx

C) brentuximab vedotin. An ADC is a three-block “engine” -- antibody-linker-drug -- and each part of the composite molecule has to be carefully selected and assembled. Considered as an armed-antibody, an ADC is a bi-dentate construction where both parts (antibody and drug) of the molecule combine their effect to ensure selectivity and potency. The role of the linker arm is of paramount importance demanding a fine tuning to execute the controlled release and delivery of the two active components in the tumor environment.

Structure of brentuximab vedotin